eoc cells  (MedChemExpress)

Journal: bioRxiv

Article Title: NLRP3 inflammasome-related microglial pyroptosis in EcoHIV infected mice

doi: 10.64898/2026.04.29.721781

Figure Lengend Snippet: (A-C) Representative confocal images showing fluorescence signals of GSDMD + (red, A-C), NLRP3 + (red, D-F) and Caspase1 + (red, G-I) in control and EcoHIV infected BV2 microglia cells w or w/o MCC950 treatment. The green fluorescence signals of eGFP signify the EcoHIV-infected microglia in BV2 cell line in vitro . The dual-labeling of EcoHIV + /GSDMD + (C), EcoHIV + /NLRP3 + (F) and EcoHIV + /Caspase1 + (I) show the colocalization of targeted proteins in EcoHIV-infected cells. (J-L) Quantification of integrative density of HLA-DR (J), PD-1 (K) and Ki67 (L) expression in immunofluorescence-stained EcoHIV + cells, classified by HIV and MCC950 status. Data are presented as mean ± SEM; p-values determined by t -test are indicated. Scale bar, 50 µm.

Article Snippet: BV2 cell line was purchased from ATCC (Cat. No. CRL-2469, ATCC) and cultured in DMEM/F12 growth medium with 10% fetal serum at 37°C, 5% CO condition.

Techniques: Fluorescence, Control, Infection, In Vitro, Labeling, Expressing, Immunofluorescence, Staining

Journal: bioRxiv

Article Title: NLRP3 inflammasome-related microglial pyroptosis in EcoHIV infected mice

doi: 10.64898/2026.04.29.721781

Figure Lengend Snippet: (A-C) Representative confocal images showing fluorescence signals of HLA-DR + (red, A-C), PD-1 + (red, D-F) and Ki67 + (red, G-I) in control and EcoHIV-infected BV2 microglia cells with or without MCC950 treatment. The green fluorescence signals of eGFP stand for the EcoHIV-infected microglia in BV2 cell line in vitro . The dual-labeling of EcoHIV + /HLA-DR + (C), EcoHIV + /PD-1 + (F) and EcoHIV + /KI67 + (I) show the colocalization of targeted proteins in EcoHIV-infected cells. (J-L) Quantification of integrative density of HLA-DR (J), PD-1 (K) and Ki67 (L) expression in immunofluorescence-stained EcoHIV + cells, classified by HIV and MCC950 status. Data are presented as mean ± SEM; p-values determined by t -test are indicated. Scale bar, 50 µm.

Article Snippet: BV2 cell line was purchased from ATCC (Cat. No. CRL-2469, ATCC) and cultured in DMEM/F12 growth medium with 10% fetal serum at 37°C, 5% CO condition.

Techniques: Fluorescence, Control, Infection, In Vitro, Labeling, Expressing, Immunofluorescence, Staining

Journal: bioRxiv

Article Title: Developing a Multimodal miR-15a Mimic to Overcome PARP Inhibitor Resistance in Epithelial Ovarian Cancer

doi: 10.64898/2026.04.20.719456

Figure Lengend Snippet: (A) Schematic representation of hsa-miR-15a and MTX-5-FU-Gem-miR-15a, showing incorporation of 5-fluorouracil and gemcitabine into the miR-15a backbone and conjugation of methotrexate (MTX) to the passenger strand. (B-E) Dose-response curves showing cell viability following treatment with MTX-5-FU-Gem-miR-15a, unmodified miR-15a, and olaparib in SK-OV-3 (B), OVCAR-3 (C), A2780 (D), and UWB1.289 (E) cells. Data represent mean ± SD from n = 4 biological replicates.

Article Snippet: Human epithelial ovarian cancer (EOC) cell lines SK-OV-3, OVCAR-3, A2780, and UWB1.289 were obtained from the American Type Culture Collection (ATCC) and MilliporeSigma.

Techniques: Conjugation Assay

Journal: bioRxiv

Article Title: Developing a Multimodal miR-15a Mimic to Overcome PARP Inhibitor Resistance in Epithelial Ovarian Cancer

doi: 10.64898/2026.04.20.719456

Figure Lengend Snippet: (A) Representative histograms of DNA content (PI staining) in only negative control and MTX-5-FU-Gem-miR-15a treatment showing cell cycle distribution in SK-OV-3, OVCAR-3, A2780, and UWB1.289 cells following treatment. (B) Quantification of cell cycle distribution after treatment shown as fold change in G2/S ratio relative to negative control across cell lines. (C) Representative Annexin V/PI flow cytometry plots showing apoptosis in indicated cell lines. (D) Quantification of apoptotic cells (early + late apoptosis) shown as fold change relative to control. (E) Western blot analysis showing expression of cleaved PARP, BCL-2, BAX, and BAK following treatment; β-actin serves as a loading control. Data represent mean ± SD from n = 3 biological replicates. Statistical significance between two groups was determined using two-tailed Student’s t test. ns, not significant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.

Article Snippet: Human epithelial ovarian cancer (EOC) cell lines SK-OV-3, OVCAR-3, A2780, and UWB1.289 were obtained from the American Type Culture Collection (ATCC) and MilliporeSigma.

Techniques: Staining, Negative Control, Flow Cytometry, Control, Western Blot, Expressing, Two Tailed Test

Journal: bioRxiv

Article Title: Developing a Multimodal miR-15a Mimic to Overcome PARP Inhibitor Resistance in Epithelial Ovarian Cancer

doi: 10.64898/2026.04.20.719456

Figure Lengend Snippet: (A, C, E) Western blot analysis of canonical miR-15a target proteins in ovarian cancer cells treated with negative control, miR-15a, MTX-5-FU-Gem-miR-15a, or 5-FU + gemcitabine. Panel A, SK-OV-3; panel C, OVCAR-3; panel E, UWB1.289. (B, D, F) Densitometric quantification of the corresponding western blots normalized to β-actin. Data represent mean ± SD from n = 3 biological replicates. Statistical significance between two groups was determined using two-tailed Student’s t test. ns, not significant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.

Article Snippet: Human epithelial ovarian cancer (EOC) cell lines SK-OV-3, OVCAR-3, A2780, and UWB1.289 were obtained from the American Type Culture Collection (ATCC) and MilliporeSigma.

Techniques: Western Blot, Negative Control, Two Tailed Test

Journal: bioRxiv

Article Title: Developing a Multimodal miR-15a Mimic to Overcome PARP Inhibitor Resistance in Epithelial Ovarian Cancer

doi: 10.64898/2026.04.20.719456

Figure Lengend Snippet: (A-C) Dose-response curves for MTX-5-FU-Gem-miR-15a and olaparib in olaparib-resistant OVCAR-3/OlaR (A), SK-OV-3/OlaR (B), and UWB1.289/OlaR (C) cells. (D) Representative cell cycle histograms (PI staining) and quantification of fold change in G2/S ratio in resistant cell lines. (E) Representative Annexin V/PI plots and quantification of total apoptotic cells (early + late apoptosis). (F-G) Dose-response analysis of cell viability in OVCAR-3 (F) and SK-OV-3 (G) spheroid cultures treated with increasing concentrations of MTX-5-FU-Gem-miR-15a or olaparib. (H) Western blot analysis of WEE1, CHK1, CCND1, and BCL-2 in OVCAR-3 spheroid cultures following treatment; β-actin serves as the loading control. Data represent mean ± SD from n = 3 biological replicates. Statistical significance between two groups was determined using two-tailed Student’s t test. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.

Article Snippet: Human epithelial ovarian cancer (EOC) cell lines SK-OV-3, OVCAR-3, A2780, and UWB1.289 were obtained from the American Type Culture Collection (ATCC) and MilliporeSigma.

Techniques: Staining, Western Blot, Control, Two Tailed Test

Journal: bioRxiv

Article Title: Developing a Multimodal miR-15a Mimic to Overcome PARP Inhibitor Resistance in Epithelial Ovarian Cancer

doi: 10.64898/2026.04.20.719456

Figure Lengend Snippet: (A) Schematic of the in vivo experimental design and treatment schedule. (B) Representative bioluminescence images of parental SK-OV-3 xenografts at endpoint. (C) Tumor growth curves over time for vehicle- and MTX-5-FU-Gem-miR-15a-treated parental xenografts. (D) Kaplan-Meier survival analysis of parental xenografts. (E) Serum AST and ALT measurements evaluating treatment-associated toxicity. (F) Representative bioluminescence images of resistant SK-OV-3/OlaR xenografts treated with vehicle, intravenous MTX-5-FU-Gem-miR-15a, or intraperitoneal MTX-5-FU-Gem-miR-15a. (G) Tumor growth curves over time for resistant xenografts. (H) Proposed mechanistic model of MTX-5-FU-Gem-miR-15a activity. Data represent mean ± SD. Statistical significance for tumor growth and body weight analyses was determined using two-way ANOVA with appropriate post hoc testing. Survival differences were analyzed using the log-rank (Mantel-Cox) test. ns, not significant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.

Article Snippet: Human epithelial ovarian cancer (EOC) cell lines SK-OV-3, OVCAR-3, A2780, and UWB1.289 were obtained from the American Type Culture Collection (ATCC) and MilliporeSigma.

Techniques: In Vivo, Activity Assay

Journal: ACS Nano

Article Title: Nicotinamide-Loaded Peptoid Nanotubes for Energy Regeneration in Acute Brain Injury

doi: 10.1021/acsnano.5c19897

Figure Lengend Snippet: NAM-PNTs show high biocompatibility and improve the cellular energy and metabolic state in the energy-depleted, acutely injured brain. a,b, MTT data showing that both NAM-PNTs (a) and Thy-PNTs (b) result in negligible effects on cell viability compared to healthy controls at all three dosages. ( n = 10). c,d, BV-2 cells exposed to 10 min of OGD showed improvement in cell viability (AlamarBlue assay) after treatment with NAM-PNTs (c) and NAD+-PNTs (d) compared to NAM and NAD+ in free form. Readings were normalized to OGD controls. Statistical significance was calculated via ordinary two-way ANOVA ( n = 3–7). e,f,g, Sonication time impacts cell viability compared to nontreated OGD-exposed controls after exposure to 20 μg/mL of NAM-PNTs for 24 h (e), 48 h (f), and 72 h (g). Readings were normalized to OGD controls. Statistical significance was calculated via a Kruskal–Wallis test ( n = 3–6). h, Intracellular ATP levels of OGD-exposed BV-2 cells with the addition of free NAM and NAM-PNTs compared to the nontreated control. All data are presented as violin plots that show the median with the interquartile range. Statistical significance was calculated via a Kruskal–Wallis test. i,j, Schematic illustration of nanoparticle uptake (h) and exocytosis (l) assays in BV-2 cells. Figure created with Biorender.com. k. BV-2 cell uptake of DNS-PNT and PLGA–PEG nanoparticles at different administration dosages after 1 h of endocytosis. Data are presented as mean ± s.d. and statistical significance was calculated via ordinary two-way ANOVA ( n = 4). l,m, Confocal images showing DNS-PNTs (red) associated with lysosomes (Lysotracker, yellow) and BV-2 cells (tomato lectin, green; ToPro-3, blue) preincubated with inhibitors for 1 h and with (l) or without (m) inhibitors for 24 h.

Article Snippet: Murine microglia BV-2 cells were purchased from ATCC (CRL-2469) and cultured based on previous literature.

Techniques: Alamar Blue Assay, Sonication, Control